Transcept Pharmaceuticals, Inc.
| Nasdaq: TSPT
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA.